Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Dec;56(6):1152-9.
doi: 10.1161/HYPERTENSIONAHA.110.159210. Epub 2010 Oct 25.

A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension

Paul M McKie  1 , Alessandro Cataliotti, Guido Boerrigter, Horng H Chen, S Jeson Sangaralingham, Fernando L Martin, Tomoko Ichiki, John C Burnett Jr
Affiliations

A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension

Paul M McKie et al. Hypertension. 2010 Dec.

Abstract

M-atrial natriuretic peptide (ANP; M-ANP) is a novel next generation 40 amino acid peptide based on ANP, which is highly resistant to enzymatic degradation and has greater and more sustained beneficial actions compared with ANP. The current study was designed to advance our understanding of the therapeutic potential of M-ANP in a canine model of acute angiotensin II-induced hypertension with elevated cardiac filling pressures and aldosterone activation. We compare M-ANP with vehicle and equimolar human B-type natriuretic peptide, which possesses the most potent in vivo actions of the native natriuretic peptides. M-ANP significantly lowered mean arterial pressure and systemic vascular resistance. Importantly, despite a reduction in blood pressure, renal function was enhanced with significant increases in renal blood flow, glomerular filtration rate, diuresis, and natriuresis after M-ANP infusion. Although angiotensin II induced an acute increase in pulmonary capillary wedge pressure, M-ANP significantly lowered pulmonary capillary wedge pressure, pulmonary artery pressure, and right atrial pressure. Further, M-ANP significantly suppressed angiotensin II-induced activation of aldosterone. These cardiovascular and renal enhancing actions of M-ANP were accompanied by significant increases in plasma and urinary cGMP, the second messenger molecule of the natriuretic peptide system. When compared with human B-type natriuretic peptide, M-ANP had comparable cardiovascular actions but resulted in a greater natriuretic effect. These results suggest that M-ANP, which is more potent than ANP in normal canines, has potent blood pressure lowering and renal enhancing properties and may, therefore, serve as an ANP based therapeutic for acute hypertension.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST/FINANCIAL DISCLOSURES

The Mayo Foundation holds a patent for M-ANP.

Figures

Figure 1
Figure 1
Mean arterial pressure (MAP) (A) and pulmonary capillary wedge pressure (PCWP) (B) at baseline (BL), during ANG II clearance (ANG II CL), during M-ANP or vehicle infusion, and 30, 60, 90 and 120 minutes post M-ANP or vehicle infusion. *P<0.05 vs BL, †P<0.05 vs ANG II, 1-way ANOVA with Bonferroni’s multiple-comparison test. P<0.001 between M-ANP and vehicle groups for both MAP and PCWP (2-way ANOVA). ‡P<0.05 for M-ANP vs vehicle at a specific time point, 2-way ANOVA with Bonferroni posttests.
Figure 2
Figure 2
Renal blood flow (RBF) (A), glomerular filtration rate (GFR) (B), urinary water excretion (UV) (C), and urinary sodium excretion (UNaV) (D) at baseline (BL), during M-ANP or vehicle infusion, and 30, 60, 90 and 120 minutes post M-ANP or vehicle infusion. *P<0.05 vs BL, †P<0.05 vs ANG II, 1-way ANOVA with Bonferroni’s multiple-comparison test. P<0.001 between M-ANP and vehicle groups for RBF, GFR, UV, and UNaV (2-way ANOVA). ‡P<0.05 for M-ANP vs vehicle at a specific time point, 2-way ANOVA with Bonferroni posttests.
Figure 3
Figure 3
Plasma 3′,5′-cyclic guanosine monophosphate (cGMP) (A), urinary cGMP excretion (B), and plasma aldosterone (C) at baseline (BL), during M-ANP or vehicle infusion, and 30, 60, 90 and 120 minutes post M-ANP or vehicle infusion. *P<0.05 vs BL, †P<0.05 vs ANG II, 1-way ANOVA with Bonferroni’s multiple-comparison test. P<0.001 between M-ANP and vehicle groups for plasma cGMP, urinary cGMP excretion, and plasma aldosterone (2-way ANOVA). ‡P<0.05 for M-ANP vs vehicle at a specific time point, 2-way ANOVA with Bonferroni posttests.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol. 2009:341–366. - PMC - PubMed
    1. Cody RJ, Atlas SA, Laragh JH, Kubo SH, Covit AB, Ryman KS, Shaknovich A, Pondolfino K, Clark M, Camargo MJ. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest. 1986;78:1362–1374. - PMC - PubMed
    1. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, Najjar SS, Zhao JH, Heath SC, Altshuler D, Strachan DP, Laan M, Meneton P, Wareham NJ, Uda M, Jarvelin MR, Mooser V, Melander O, Loos RJ, Elliott P, Abecasis GR, Caulfield M, Munroe PB. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet. 2009;41:666–676. - PMC - PubMed
    1. Newton-Cheh C, Larson MG, Vasan RS, Levy D, Bloch KD, Surti A, Guiducci C, Kathiresan S, Benjamin EJ, Struck J, Morgenthaler NG, Bergmann A, Blankenberg S, Kee F, Nilsson P, Yin X, Peltonen L, Vartiainen E, Salomaa V, Hirschhorn JN, Melander O, Wang TJ. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet. 2009;41:348–353. - PMC - PubMed
    1. John SW, Krege JH, Oliver PM, Hagaman JR, Hodgin JB, Pang SC, Flynn TG, Smithies O. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science. 1995;267:679–681. - PubMed

Publication types

MeSH terms